Exagen to Announce Fourth Quarter and Full Year Financial Results on March 16, 2021

March 2, 2021 8:00 AM EST

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading autoimmune organization, will release financial results for the quarter and year ended December 31, 2020 after the market close on Tuesday, March 16, 2021. Ron Rocca, President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will host a conference call to review the Company’s results at 4:30 PM Eastern Time (1:30 PM Pacific Time).

Interested parties may access the conference call by dialing (877) 407-3982 (U.S.) or (201) 493-6780 (international). Participants wishing to access the call via webcast should use the link posted on the Exagen investor relations website at https://investors.exagen.com/

A replay of the conference call will be available until Tuesday, March 23, 2021 at 11:59 PM Eastern Time (8:59 PM Pacific Time). Interested parties may access the replay of the conference call by dialing (844) 512-2921 (U.S.) or (412) 317-6671 (international) using passcode 13716870.   Additionally, a recording of the webcast will be available using the link on the Exagen investor relations website approximately 30 minutes after the call concludes.

About Exagen Inc.

Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE® brand, several of which are based on our proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. Exagen’s goal is to enable providers to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including rheumatoid arthritis and lupus. For further information please visit www.exagen.com.

CONTACTS:

Investors

Westwicke PartnersMike CavanaughMike.Cavanaugh@westwicke.com646.677.1838

Company Contact

Exagen Inc.Kamal Adawi, Chief Financial OfficerKAdawi@exagen.com 760.477.5514

Primary Logo

Source: Exagen Inc.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Globe Newswire, Press Releases

Related Entities

Earnings